D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

NCT06643208 | Recruiting

• 1 other identifier: TALENP005
• Study Type: observational
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.

Conditions

Intrahepatic Cholangiocarcinoma

Outcome Measures

Primary Outcomes (1)

• Objective response rate, ORR

  The Objective response rate (ORR) was defined as the complete response (CR) rate or the partial response (PR) rate according to RECIST v1.1 criteria.

  Four weeks after the initiation of medication

Secondary Outcomes (4)

• Overall survival, OS

  From date of enrollment until the date of death from any cause, assessed up to 60 months

• Progression-free survival, PFS

  From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

• Disease control rate, DCR

  Four weeks after the initiation of medication

• Treatment-related adverse events, TRAEs treatment-related adverse events

  From the initiation of medication, with recordings made whenever an adverse reaction occurs, assessed up to 12 months

Study Arms (1)

Combination therapy group

Patients with unresectable cholangiocarcinoma were treated with D-TACE-HAIC (GEMOX regimen) combined with envafolimab and lenvatinib

Drug: TACE-HAIC, Envafolimab and Lenvatinib

Interventions

TACE-HAIC, Envafolimab and Lenvatinib DRUG

TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib

Combination therapy group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with unresectable intrahepatic cholangiocarcinoma

You may qualify if:

• \. Ages of 18 and 75;
• \. Child-Pugh liver function grade: A/B;
• \. ECOG score (see annex for scoring standards) : ≤1 score;
• \. ICC was confirmed by pathology and evaluated by two senior hepatobiliary surgeons as unresectable for surgery (including multiple intrahepatic lesions, local vascular invasion, local lymph node metastasis, and distant metastasis);
• \. According to RECIST 1.1 criteria, the patient has at least one measurable lesion (the CT/MRI scan diameter of the lesion can be measured ≥10mm, and the lesion has not received local treatment such as radiotherapy or freezing);
• \. The expected survival time is greater than 3 months;
• \. Patients who had not received any tumor-related targeting, immunization, radiotherapy or chemotherapy before enrollment;
• \. Functional indexes of vital organs met the following requirements: · Routine blood: absolute neutrophil count ≥1.5×109/L, Hb≥9.0g/L, PLT≥75×109/L; · Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN) (≤2.5 times ULN after biliary drainage in patients with obstructive jaundice); Alanine aminotransferase (ALT), aspartate aminotransferase (AST)≤ 5x ULN, albumin ≥30g /L; · Renal function: serum creatinine ≤1.5mg/dL, creatinine clearance ≥60ml /min; · Coagulation function: International standardized ratio (INR) and activated partial thromboplastin time (APTT)≤1.5 times ULN;
• \. No history of severe arrhythmia or heart failure; No history of severe ventilation dysfunction or severe pulmonary infection;
• \. Women of childbearing age should agree to use contraception during the use of medication and for 6 months after the end of medication; Patients who had a negative serum or urine pregnancy test in the 7 days prior to study enrollment and must be non-lactating patients, men should consent to use contraception during the study period and for 6 months after the end of the study period.

You may not qualify if:

• \. Patients who have previously received other local anti-tumor treatments (such as radiotherapy, radiofrequency ablation, etc.), who are allowed to relapse 6 months after previous surgery, and who are allowed to undergo biliary drainage (including PTCD and biliary stent implantation);
• \. History of allergy to gemcitabine, oxaliplatin, Envolizumab, Renvastinib and its components;
• \. A history of other malignant tumors within the past 5 years or at the same time, except cured basal cell carcinoma of the skin, cervical carcinoma in situ and thyroid papillary carcinoma;
• \. Patients who have previously received an organ transplant or are planning to receive an organ transplant;
• \. The presence of any active autoimmune disease or patients with autoimmune disease and expected recurrence (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes);
• \. History of immune deficiency; The patient is taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes and continues to use it within 2 weeks prior to signing the informed consent;
• \. Known hereditary or acquired bleeding (e.g. coagulation disorders) or thrombotic tendencies, e.g. in hemophiliacs; Is currently or recently (within 10 days prior to the start of study therapy) used full dose oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (prophylactic use of low-dose aspirin, low-molecular weight heparin permitted);
• \. Serious infections, such as severe pneumonia, bacteremia, and comorbiditis requiring hospitalization, occurred within 4 weeks prior to the first use of the study drug; Baseline chest imaging findings indicate active lung inflammation, signs and symptoms of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment (excluding prophylactic antibiotic use);
• \. Patients with mental illness; Have a history of psychotropic substance abuse, alcoholism and drug use;
• \. Pregnant or lactating women;
• \. Those who, according to the judgment of the researcher, should not participate in this experiment for other reasons;

Sponsors & Collaborators

• Fujian Provincial Hospital: lead

Study Sites (1)

Fujian Provincial Hospital

Fuzhou, Fujian, China

RECRUITING

MeSH Terms

Conditions

Cholangiocarcinoma

Interventions

envafolimab; lenvatinib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Maolin Yan, Doctor

  Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital

  STUDY CHAIR

Central Study Contacts

Maolin Yan, Doctor

CONTACT

15960066307; yanmaolin74@163.com

Junyi Wu, Doctor

CONTACT

15059162797; 1248087863@qq.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 13, 2024
• First Posted: October 16, 2024
• Study Start: July 1, 2024
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: June 26, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)